In a pivotal move in the cybersecurity landscape, it has been disclosed that US Kaspersky antivirus accounts have been acquired by UltraAV, which operates under the Pango Group umbrella. This transition stems from a significant event earlier in the year when Kaspersky was mandated to exit the US market. The Biden administration, citing national security concerns, issued a Final Determination via the Department of Commerce’s Bureau of Industry and Security (BIS) on June 20, 2024, effectively banning Kaspersky’s operations in the US. This measure seeks to prevent potential exploitation and data weaponization by Russian entities.
Antivirus software uniquely commands elevated system privileges to efficiently detect and eradicate deeply embedded malware. However, these same privileges can potentially be misused for espionage. The BIS has asserted that Kaspersky was reportedly under Russian direction to leverage its software’s high-level access for data collection and control over American systems.
As a result of the BIS directive, Kaspersky US will cease all business activities and halt antivirus updates by the end of September 2024. This shutdown is restricted to the US; Kaspersky’s international operations remain unaffected. In winding down its US presence, Kaspersky has sold all its US accounts to UltraAV, a domestic security firm that insists on its independence from Kaspersky.
Current Kaspersky users in the US, numbering around a million, will experience an automatic migration to UltraAV’s antivirus service unless they opt out. The pricing model for existing users will continue unchanged. However, for new customers, the cost is slated at $47.88 for the initial year, followed by $149.99 annually. The UltraAV service promises support for up to 20 devices, extending compatibility across Android, iOS (with some restrictions), Mac, and Windows platforms.
Despite advancements from tech giants like Microsoft, which offers robust built-in antivirus software free with Windows, many users prefer the comprehensive protection provided by paid services. Renowned alternatives in the market, such as AVG, Avast, Bitdefender, McAfee, and Norton, have consistently performed well according to reviews from AV Comparatives, AV Test, and Virus Bulletin. However, UltraAV is yet to be evaluated by these leading testing platforms, leaving its real-world efficacy somewhat undetermined.
This transition marks a critical episode in the cybersecurity sector as users and experts alike watch closely to see how UltraAV’s service performs and adapts in safeguarding American consumers.
